Barlas Buyuktimkin, Ph.D.
Affiliations: | 2011 | Pharmaceutical Chemistry | University of Kansas, Lawrence, KS, United States |
Area:
Pharmacy, Immunology, General BiophysicsGoogle:
"Barlas Buyuktimkin"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Teruna J. Siahaan | grad student | 2011 | University of Kansas | |
| (Utilizing antigenic peptide and adhesion molecule conjugates to suppress autoimmune disease in animal models.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Büyüktimkin B, Kiptoo P, Siahaan TJ. (2014) Bifunctional Peptide Inhibitors Suppress Interleukin-6 Proliferation and Ameliorates Murine Collagen-Induced Arthritis. Journal of Clinical & Cellular Immunology. 5 |
| Kiptoo P, Büyüktimkin B, Badawi AH, et al. (2013) Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology. 172: 23-36 |
| Büyüktimkin B, Manikwar P, Kiptoo PK, et al. (2013) Vaccinelike and prophylactic treatments of EAE with novel I-domain antigen conjugates (IDAC): targeting multiple antigenic peptides to APC. Molecular Pharmaceutics. 10: 297-306 |
| Büyüktimkin B, Wang Q, Kiptoo P, et al. (2012) Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis. Molecular Pharmaceutics. 9: 979-85 |
| Manikwar P, Büyüktimkin B, Kiptoo P, et al. (2012) I-domain-antigen conjugate (IDAC) for delivering antigenic peptides to APC: synthesis, characterization, and in vivo EAE suppression. Bioconjugate Chemistry. 23: 509-17 |
| Manikwar P, Kiptoo P, Badawi AH, et al. (2012) Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases. Medicinal Research Reviews. 32: 727-64 |